A bold concern drives this discussion: excessive drinking is a pervasive issue, and a £3 pill could help many curb their bingeing without sacrificing daily life. But here’s where it gets controversial: could a medication play a bigger role in reducing festive overindulgence than traditional therapies? The following rewrite keeps the essential facts and adds clarity, context, and practical implications for readers exploring this option.
There is growing interest in a medication called naltrexone, priced around £3 per dose, which some experts are dubbing the “Ozempic of alcohol.” It works by dampening the brain’s reward signals after drinking, which can significantly cut down the urge to continue consuming alcohol. In studies, roughly four out of five people who take naltrexone before drinking reduce their intake substantially or stop drinking altogether. This has led some to compare its potential impact on alcohol use to the way drugs like Ozempic and Mounjaro reduce food cravings in weight management.
NHS guidelines currently recommend no more than 14 units of alcohol per week, which is about six pints of beer or ten small glasses of wine. Yet a quarter of British adults regularly exceed this limit. December often sees a rise in drinking, with more people hospitalized for alcohol-related problems as a consequence.
Privately, naltrexone can cost about £100 a month, but many users end up saving money by drinking less. Some experts advocate for wider NHS access, arguing that GPs should be able to prescribe naltrexone to millions who binge drink, rather than limiting it to those with severe alcohol dependency.
“This pill has shown greater effectiveness in reducing drinking than some therapies like counselling and rehabilitation, yet many GPs aren’t aware of it,” says Dr. Janey Merron, an alcohol specialist at the Sinclair Method UK clinic. “It’s genuinely frustrating for the many people missing out.”
Recent data show that nearly one in five British adults admits to binge drinking in the past week, defined as more than eight units in a single session. Alcohol-related conditions account for more than 320,000 hospital admissions each year, with over 10,000 deaths largely due to liver disease. Alcohol-related deaths rose to a record high last year, continuing a troubling trend post-pandemic. Regular heavy drinking is also a known risk factor for several cancers.
Naltrexone is not a new drug; it has been available on the NHS since the 1980s. The medicine works by blocking brain receptors that respond to alcohol, reducing the pleasurable feeling typically associated with drinking. By weakening this reinforcement, the brain can “unlearn” the association between alcohol and the release of feel-good chemicals that fuel craving.
When taken about an hour before drinking, naltrexone has demonstrated an approximate 80% success rate in helping users cut back or abstain. By comparison, many rehabilitation programs, including Alcoholics Anonymous, report success rates below 15% according to the World Health Organization.
Some researchers also note a curious, if seemingly unrelated, finding: people with blue eyes have, on average, higher alcohol consumption than those with brown eyes. Clinics typically provide naltrexone alongside therapy and lifestyle guidance. Within six months to a year, many patients experience a substantial reduction in drinking and often lose the compulsion to drink, even when a rare occasion leads to a drink.
“At that point, the brain is basically reprogrammed to resemble its pre-drinking state,” Dr. Merron explains. “Many people simply aren’t interested in drinking at all anymore.”
Not everyone agrees that GPs should routinely prescribe naltrexone. Some doctors warn that most GPs lack experience with the medication and would require training and access to psychological support services, which adds to already heavy workloads.
Dr. Merron, however, argues that the NHS approach tends to overemphasize treating severe alcoholism while overlooking the millions who drink dangerously without meeting strict addiction criteria. “My typical patient isn’t what you picture as an alcoholic,” she notes. “Many high-functioning professionals and even stressed parents struggle with drinking. Naltrexone should be available to anyone for whom alcohol has become a problem.”
A case in point is Katie, a 37-year-old from the East Midlands who asked not to use her surname. After the birth of her second child, she began drinking heavily, almost every night for weeks, which affected her family. Seeking help, Katie discovered the Sinclair Method and naltrexone online. A few months in, she reports a dramatic shift: she drinks less, enjoys more sober days, and feels more mindful when she does drink. Looking back, she says she hardly recognizes her former self.
Controversial questions linger: should the NHS broaden access to naltrexone for all who struggle with regular binge drinking, and what supports would be needed to implement this safely and effectively? Are there risks or downsides to wide use, such as side effects, misuse, or dependence on medication to manage behavior? Share your thoughts and experiences in the comments to fuel a constructive discussion.
